Zero-Cost Low-Dose Heavy Ion Therapy for Benign Prostatic Hyperplasia – Fully Enrolled

Zero-Cost Low-Dose Heavy Ion Therapy for Benign Prostatic Hyperplasia – Fully Enrolled

I. Project Research Background

As the aging population in China continues to deepen, the incidence of benign prostatic hyperplasia (BPH) among middle-aged and elderly men is increasing year by year, making it a highly prevalent chronic disease that severely affects the quality of daily life of men.

To further support the high-quality development of China's heavy-ion technology, build upon previous work to deepen clinical application research, and vigorously promote iterative upgrades of heavy-ion therapy technology, the Department of Urology and the Third Department of Radiotherapy at the Heavy Ion Center of Gansu Wuwei Cancer Hospital have jointly launched the "Clinical Study on the Efficacy and Safety of Low-Dose Heavy Ion Radiotherapy for Benign Prostatic Hyperplasia."

This study aims to improve the clinical symptoms and quality of life of patients with benign prostatic hyperplasia, while aligning with international diagnostic and treatment standards, and to explore and establish a standardized clinical diagnosis and treatment system for BPH using China's heavy-ion system, thereby providing patients with better treatment outcomes and safer therapeutic options.

Currently, the project has passed scientific review for clinical research and ethical approval by the Medical Ethics Committee, and is now publicly and continuously recruiting clinical study participants from the general population.

II. Project Inclusion Criteria

· Aged between 60 and 85 years;
· Presence of moderate to severe lower urinary tract symptoms, defined as IPSS ≥ 8, and confirmed as benign prostatic hyperplasia by prostate ultrasound;
· Poor symptom improvement after at least 3 months of standard medical therapy, inability to tolerate adverse drug reactions, or patient refusal of surgical treatment; or inability to tolerate surgery due to underlying cardiopulmonary, cerebral, or other medical conditions;
· Generally good performance status, with no organ dysfunction, and able to tolerate the proposed treatment;
· Willing to voluntarily participate in the study and able to comply with treatment and follow-up.

Note: The above criteria are the main eligibility requirements. Final enrollment eligibility will be determined by the investigator in accordance with the study protocol.

III. Patient Rights

1. The hospital will cover the research funding for this project, and participants will not bear any costs for heavy ion therapy;
2. A multidisciplinary expert team (MDT) consisting of urology, radiotherapy, and other specialists will develop a personalized treatment plan for you;
3. After treatment, we will conduct close follow-up with you and provide guidance on subsequent treatment options.

IV. Contact Information

Clinic Address:

Gansu Wuwei Cancer Hospital · Wuwei Heavy Ion Center

Consultation Hotline:

400-6096666 / 19893507669

Evaluation Process:

Submit documents → MDT assessment → Screening and enrollment → Simulation and treatment → Regular follow-up

V. Contact Information

Address: Wuwei Heavy Ion Center, Gansu Wuwei Cancer Hospital

VI. Contact Person

Director Tang Juntian (Department of Urology)

+86 13639352510    1st Floor, Building 6, Heavy Ion Campus

Director Chen Weizuo (Third Department of Radiotherapy)

+86 13519351968    1st Floor, Building 5, Heavy Ion Campus

Gansu Wuwei Cancer Hospital (Wuwei Institute of Medical Sciences)

（甘）医广【2025】第11-14-387号